Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers

Table 1 Summary of Kaplan–Meier survival analysis of the E0771 in-vivo study (Fig. 3)

	Median survival
	Control (c44)	mch1N11	aPD-1	mch1N11 + aPD-1
Days	25	32	55	Undefined
Hazard ratio	–	0.1915	0.089	0.04557
CI of HR at 95 %	–	0.003086–0.03911	0.0001420–0.004134	3.222 × 10^–5–0.001361
Mice with complete regression	0	0	2	6

Data include median survival (days), hazard ratio (HR) confidence interval (CI) at 95 % of HR, and number of animals with each treatment that experienced complete tumor regression

ISSN: 1465-542X